secwatch.observer — SEC 8-K summary
======================================

Issuer:     SkinHealth Systems Inc. (SKIN)
CIK:        0001818093
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001628280-23-038598
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beauty Health CEO Andrew Stanleick departs; director Marla Beck named interim CEO
--------------------------------------------------------------------------------

- Andrew Stanleick steps down as CEO and board member effective Nov 19, 2023; will advise through Dec 31, 2023.
- Director Marla Beck appointed interim CEO from Nov 20, 2023, for a 6-month term; resigns from audit committee.
- Beck co-founded Bluemercury; led it as CEO for 22 years including post-acquisition by Macy's.
- Interim CEO compensation: $200K monthly base (min. 4 months), $500K RSUs ratably vesting over term, $400K change-in-control bonus.
- Board has initiated a formal search for a permanent CEO; Saunders expresses confidence in strategy and long-term growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818093/000162828023038598/0001628280-23-038598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818093/000162828023038598/skin-20231110.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer